Comtois R, Beauregard H, Hardy J, Robert F, Somma M
Department of Medicine, Notre-Dame Hospital, University of Montreal, Quebec, Canada.
Clin Endocrinol (Oxf). 1993 Jun;38(6):601-7. doi: 10.1111/j.1365-2265.1993.tb02141.x.
This study was designed to compare the clinical and biochemical features of patients with Cushing's disease without pathological evidence of pituitary adenoma (n = 11) to those in whom a pituitary ACTH adenoma was documented (n = 11).
The clinical and biochemical features of 11 patients with Cushing's disease without pathological evidence of pituitary adenomas were compared to 11 subjects with ACTH-secreting adenomas. The patients underwent transsphenoidal microsurgery between 1979 and 1989. During surgery, when an adenoma was not visualized, a partial hypophysectomy of the central mucoid wedge was performed.
Cushing's disease was established by the clinical features of hypercortisolism and the high levels of 24-hour free urinary cortisol with no suppression in response to low, but with suppression in response to high, doses of dexamethasone. Basal and post TRH-GnRH plasma prolactin, FSH and LH levels were assessed in each patient before transsphenoidal microsurgery.
Similar results were observed in patients with and without ACTH-secreting adenomas regarding cure rate, and free urinary cortisol levels both basal and after 2 days of dexamethasone, 8 mg daily. After surgery, plasma cortisol levels in cured patients were lower in subjects with ACTH-secreting adenomas than in those without pituitary tumours (P < 0.05). Areas under the curve of PRL (P < 0.002) and LH (P < 0.04) were significantly higher in patients without pituitary adenoma after TRH-GnRH administration. Compared to controls, the peak prolactin level after TRH-GnRH administration was higher in patients without pituitary adenoma (P < 0.005) and lower in those with ACTH adenoma (P < 0.005). Furthermore, a peak prolactin level equal to or greater than 1410 mU/l during the TRH-GnRH test was found in 11/11 patients without ACTH adenoma and 3/11 patients in the other group (P < 0.001), while the CT-scan findings were suggestive of pituitary adenoma in six patients of each group.
This study suggests that patients with Cushing's disease without pituitary adenomas can be distinguished from those with ACTH-secreting adenomas by their high prolactin levels after TRH-GnRH administration.
本研究旨在比较无垂体腺瘤病理证据的库欣病患者(n = 11)与有垂体促肾上腺皮质激素(ACTH)腺瘤记录的患者(n = 11)的临床和生化特征。
将11例无垂体腺瘤病理证据的库欣病患者的临床和生化特征与11例分泌ACTH腺瘤患者进行比较。这些患者在1979年至1989年间接受了经蝶窦显微手术。手术过程中,若未发现腺瘤,则对中央黏液样楔形物进行部分垂体切除术。
根据皮质醇增多症的临床特征以及24小时尿游离皮质醇水平升高且对低剂量地塞米松无抑制反应、对高剂量地塞米松有抑制反应来确诊库欣病。在经蝶窦显微手术前,评估每位患者的基础及促甲状腺激素释放激素-促性腺激素释放激素(TRH-GnRH)刺激后的血浆催乳素、促卵泡生成素(FSH)和促黄体生成素(LH)水平。
在分泌ACTH腺瘤患者和无分泌ACTH腺瘤患者中,关于治愈率以及基础和每日8毫克地塞米松治疗2天后的尿游离皮质醇水平,观察到相似的结果。手术后,分泌ACTH腺瘤患者中治愈患者的血浆皮质醇水平低于无垂体肿瘤患者(P < 0.05)。给予TRH-GnRH后,无垂体腺瘤患者的催乳素(PRL)曲线下面积(P < 0.002)和LH曲线下面积(P < 0.04)显著更高。与对照组相比,给予TRH-GnRH后,无垂体腺瘤患者的催乳素峰值水平更高(P < 0.005),而分泌ACTH腺瘤患者的催乳素峰值水平更低(P < 0.005)。此外,在TRH-GnRH试验期间,催乳素峰值水平等于或大于1410 mU/l的情况在11/11例无ACTH腺瘤患者和3/11例另一组患者中出现(P < 0.001),而每组各有6例患者的CT扫描结果提示垂体腺瘤。
本研究表明,给予TRH-GnRH后催乳素水平高可将无垂体腺瘤的库欣病患者与分泌ACTH腺瘤患者区分开来。